首页> 美国卫生研究院文献>Pharmaceutics >Preparation and Optimization of In Situ Gel Loaded with Rosuvastatin-Ellagic Acid Nanotransfersomes to Enhance the Anti-Proliferative Activity
【2h】

Preparation and Optimization of In Situ Gel Loaded with Rosuvastatin-Ellagic Acid Nanotransfersomes to Enhance the Anti-Proliferative Activity

机译:瑞舒伐他汀-鞣花酸纳米转移体原位凝胶的制备及优化以增强抗增殖活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of this study was to develop an optimized sustained-release nanotransfersomes (NTS) based in situ gel formulation of rosuvastatin (RO) combined with ellagic acid (EA) antioxidant, to enhance cytotoxic and anti-proliferative activity against tongue carcinoma. The concentrations of lecithin, Tween 80, and -tocopherol polyethylene glycol succinate (TPGS) were considered as independent variables. Particle size, entrapment, and stability were selected as dependent variables. The obtained formulation containing 25% lecithin, 20% Tween 80, and TPGS 15% fulfilled the prerequisites of the optimum formulation. RO-NTS loaded in situ gel was prepared and optimized for concentrations of Poloxamer 407, and Carbopol, using statistical design. Drug release from in situ gel showed a sustained release profile. The RO IC50 was decreased by half for the in situ gel in comparison to plain RO and RO-EA-NTS. A significant amount of caspase-3 was detected in all the formulation treatments. The studies indicated that EA’s synergistic anti-oxidant effect owing to a high affinity to the PGP efflux transporter and higher penetration in the RO-NTS formulation led to a higher inhibition against human chondrosarcome-3 cancer cell lines. RO-EA NTS–loaded in situ gel had a sustained release that could be significant in localized therapy as an alternative to surgery in the treatment of aggressive tongue carcinoma.
机译:这项研究的目的是开发基于瑞舒伐他汀(RO)和鞣花酸(EA)抗氧化剂的原位凝胶制剂的优化的缓释纳米转移体(NTS),以增强针对舌癌的细胞毒性和抗增殖活性。卵磷脂,吐温80和生育酚聚乙二醇琥珀酸酯(TPGS)的浓度被视为自变量。选择粒径,截留率和稳定性作为因变量。所获得的包含25%卵磷脂,20%Tween 80和TPGS 15%的配方满足了最佳配方的先决条件。使用统计学设计,制备了原位装载RO-NTS的凝胶,并针对泊洛沙姆407和Carbopol的浓度进行了优化。从原位凝胶释放的药物显示出持续释放曲线。与普通RO和RO-EA-NTS相比,原位凝胶的RO IC50降低了一半。在所有制剂处理中均检测到大量的caspase-3。研究表明,EA对PGP外排转运蛋白具有高度亲和力,并且在RO-NTS制剂中具有较高的渗透性,因此具有协同抗氧化作用,因此对人软骨肉瘤3癌细胞系的抑制作用更高。装有RO-EA NTS的原位凝胶具有持续释放的功能,这在局部治疗中可能是重要的,可替代侵袭性舌癌的手术治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号